

# A trial to evaluate the safety, tolerability, and pharmacokinetics of AQ280 in healthy subjects

<b>Submission date</b> 30/04/2022	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 08/07/2022	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 06/04/2023	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

AQ280 belongs to a class of drugs known as highly selective JAK-1 inhibitors. JAK-1 inhibitors interrupt the inflammatory pathway in the body. It is hoped that AQ280 will be an effective new treatment for a condition called eosinophilic oesophagitis, a chronic, allergic inflammatory condition of the oesophagus (the tube connecting the mouth to the stomach).

### Who can participate?

Healthy volunteers aged 18 to 65 years.

### What does the study involve?

Part A will comprise a single dose, sequential group, escalating-dose design; also incorporating a single group, 2 period crossover arm investigating the effect of dosing AQ280 with food compared to dosing whilst fasting. Approximately 40 participants are planned to be studied in 5 cohorts (Cohorts A1 to A5; with one of the cohorts including the food-effect evaluation). In each cohort, 6 participants will receive AQ280 and 2 participants will receive placebo. Each participant will reside at the study site from Day -1 to Day 3 of the treatment period and a safety follow-up phone call will be conducted 1 week after dosing. The Day 1 dose will be administered in the fasted state in all cohorts except for treatment period 2 of the food effect cohort where it will be administered after eating a high fat breakfast.

Part B will comprise a multiple dose, sequential group, escalating-dose design. Approximately 24 participants are planned to be studied in 3 cohorts (Cohorts B1 to B3). In each cohort, 6 participants will receive AQ280 and 2 participants will receive placebo. Each participant will reside at the study site from Day -1 to Day 9. Dosing is planned to be once daily on Days 1 to 7 and a safety follow-up visit will be conducted 1 week after the final dose.

The total duration of study participation for each participant is anticipated to be approximately 6 weeks (8 weeks for the food effect cohort) in Part A and 7 weeks in Part B.

### What are the possible benefits and risks of participating?

#### Benefits:

Not provided at time of registration

**Risks:**

The starting dose has been selected based on the preclinical data with the intention that it will be a safe and well tolerated starting dose. Strict dose escalation stopping criteria will apply during the study to minimise the risk to study participants, these are based on the effects seen in animal studies as well as the side effects seen with other drugs within the same class.

Participants will be closely monitored whilst on the clinical trial for potential drug effects (eg. adverse events (particularly infections), laboratory value changes (particularly evidence of anaemia, neutropenia and thrombocytopenia), vital signs or ECG changes). Any abnormalities will be followed up until resolution.

Where is the study run from?

Aqilion AB (Sweden)

When is the study starting and how long is it expected to run for?

April 2022 to July 2023

Who is funding the study?

Aqilion AB (Sweden)

Who is the main contact?

Dr Ashley Brooks, [ashley.brooks@labcorp.com](mailto:ashley.brooks@labcorp.com)

## Contact information

**Type(s)**

Scientific

**Contact name**

Mrs Katya Uzunova

**Contact details**

Osprey House  
Maidenhead Office Park  
Westacott Way  
Maidenhead  
United Kingdom  
SL63QH  
+359 28006947  
[submissions@labcorp.com](mailto:submissions@labcorp.com)

**Type(s)**

Scientific

**Contact name**

Mrs Heather Holland

**Contact details**

Springfield House  
Hyde Street  
Leeds

United Kingdom  
LS2 9HL  
-  
heather.holland@labcorp.com

**Type(s)**  
Principal Investigator

**Contact name**  
Dr Ashley Brooks

**Contact details**  
Springfield House  
Hyde Street  
Leeds  
United Kingdom  
LS2 9LH  
+44 113 301 3521  
ashley.brooks@labcorp.com

## **Additional identifiers**

**EudraCT/CTIS number**  
Nil known

**IRAS number**  
1005473

**ClinicalTrials.gov number**  
NCT05485779

**Secondary identifying numbers**  
ARIA-1, IRAS 1005473

## **Study information**

**Scientific Title**  
A randomized, double-blind, placebo-controlled, single and multiple ascending dose and food effect evaluation trial to evaluate the safety, tolerability, and pharmacokinetics of AQ280 in healthy subjects

**Study objectives**

- To evaluate the safety and tolerability of single and multiple ascending oral doses of AQ280, and to determine a safe therapeutic range of AQ280 in healthy subjects
- To determine the PK of AQ280 after single and multiple oral doses
- To determine the PK of the AQ280 main metabolite, AQ282, after single and multiple oral doses
- To determine the effect of food on the PK of AQ280 after single oral dose

**Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 06/06/2022, London Riverside Research Ethics Committee (Level 3 Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK; +44 (0)207 104 8150, +44 (0)207 104 8013; riverside.rec@hra.nhs.uk), ref: 22/FT/0063

### **Study design**

Interventional double blind randomized single and multiple ascending dose trial with sequential groups and crossover design placebo controlled trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised cross over trial

### **Study setting(s)**

Hospital

### **Study type(s)**

Treatment

### **Participant information sheet**

Not available in web format, please use the contact details below to request a participant information sheet

### **Health condition(s) or problem(s) studied**

Allergic reaction in the gullet

### **Interventions**

Part A will comprise a single dose, sequential group, escalating-dose design; also incorporating a single group, 2 period crossover arm investigating the effect of dosing AQ280 with food compared to dosing whilst fasting. Approximately 40 participants are planned to be studied in 5 cohorts (Cohorts A1 to A5; with one of the cohorts including the food-effect evaluation). In each cohort, 6 participants will receive AQ280 and 2 participants will receive placebo. Each participant will reside at the study site from Day -1 to Day 3 of the treatment period and a safety follow-up phone call will be conducted 1 week after dosing. The Day 1 dose will be administered in the fasted state in all cohorts except for treatment period 2 of the food effect cohort where it will be administered after eating a high fat breakfast.

Part B will comprise a multiple dose, sequential group, escalating-dose design. Approximately 24 participants are planned to be studied in 3 cohorts (Cohorts B1 to B3). In each cohort, 6 participants will receive AQ280 and 2 participants will receive placebo. Each participant will reside at the study site from Day -1 to Day 9. Dosing is planned to be once daily on Days 1 to 7 and a safety follow-up visit will be conducted 1 week after the final dose.

### **Intervention Type**

Drug

### **Phase**

## Phase I

### Drug/device/biological/vaccine name(s)

AQ280

### Primary outcome measure

1. Number of TEAEs per subject daily from signed consent to end of trial
2. Clinically significant abnormalities in vital signs (systolic and diastolic blood pressure, pulse rate, and oral body temperature) multiple timepoints per day from screening until end of trial
3. Abnormal ECG (QTcF interval of >450 msec for males and >470 msec for females, or change from baseline of >30 msec) measured from Day 1 (postdose) up until 48 hours postdose in Part A and up to the follow-up visit in Part B. Safety ECG: Part A/B: from screening and on Day 1, 3, 5, 7, 8, 9
4. Clinically significant changes in laboratory evaluations on multiple days from dosing until end of trial

### Secondary outcome measures

Part A at predose and multiple timepoints up to 48 hours postdose:

1. Primary PK parameters derived from plasma concentration-time profile of AQ280: AUC<sub>0-∞</sub>, C<sub>max</sub> (AUC<sub>0-t</sub> last may be included as a primary PK parameter if AUC<sub>0-∞</sub> cannot be calculated)
2. Primary PK parameters derived from plasma concentration-time profile of the AQ280 main metabolite, AQ282: AUC<sub>0-∞</sub>, C<sub>max</sub> (AUC<sub>0-t</sub> last may be included as a primary PK parameter if AUC<sub>0-∞</sub> cannot be calculated)
3. Comparison of the primary PK parameters of AQ280 after single dose administration in the fasted state and in the fed state

Part B at predose and multiple timepoints during Day 1 and Day 7, as well as daily until end of trial:

1. Primary PK parameters derived from plasma concentration-time profile of AQ280 on Day 1 and Day 7: AUC<sub>τ</sub>, C<sub>max</sub>
2. Primary PK parameters derived from plasma concentration-time profile of the AQ280 main metabolite, AQ282, on Day 1 and Day 7: AUC<sub>τ</sub>, C<sub>max</sub>

### Overall study start date

28/04/2022

### Completion date

10/07/2023

## Eligibility

### Key inclusion criteria

1. Males or females, of any race, between 18 and 65 years of age, inclusive.
2. Body mass index between 18.0 and 32.0 kg/m<sup>2</sup>, inclusive.
3. In good health, determined by no clinically significant findings from medical history, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations at screening and check-in and from the physical examination at check-in, as assessed by the investigator (or designee).
4. Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception
5. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.

**Participant type(s)**

Healthy volunteer

**Age group**

Adult

**Lower age limit**

18 Years

**Upper age limit**

65 Years

**Sex**

Both

**Target number of participants**

64

**Key exclusion criteria**

1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
2. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).
3. History of any surgical (eg, stomach or intestinal surgery or resection) or medical condition that would potentially alter absorption, distribution, metabolism, and/or excretion of orally administered drugs. Uncomplicated appendectomy and hernia repair will be allowed. Cholecystectomy will not be allowed.
4. History of any significant infectious disease, as assessed by the investigator, within 2 weeks prior to the first dose of IMP.
5. AST and/or ALT values  $>1.2 \times$  ULN.
6. Congenital nonhemolytic hyperbilirubinaemia (including suspicion of Gilbert's syndrome).
7. Hemoglobin value, neutrophil count, and/or lymphocyte count  $<$  lower limit of normal.
8. Clinically significant abnormal ECG at screening or check-in.
9. Positive hepatitis panel and/or positive human immunodeficiency virus test. Subjects whose results are compatible with prior immunization may be included at the discretion of the investigator
10. Current active tuberculosis based on Quantiferon™ tuberculosis (TB) Gold test.

**Date of first enrolment**

01/07/2022

**Date of final enrolment**

26/06/2023

**Locations****Countries of recruitment**

United Kingdom

## Study participating centre

-

United Kingdom

-

## Sponsor information

### Organisation

Aqilion AB

### Sponsor details

Redaregatan 48

Helsingborg

Sweden

SE-252 36

-

info@aqilion.com

### Sponsor type

Industry

## Funder(s)

### Funder type

Industry

### Funder Name

Aqilion AB

## Results and Publications

### Publication and dissemination plan

Submission to regulatory authorities

Information that could allow identification of the participant will not be captured in the CRF.

Copies of any documents that are collected as part of the study data will be anonymised appropriately prior to photocopying. Information is only accessible by authorised personnel.

### Intention to publish date

10/07/2024

### Individual participant data (IPD) sharing plan

All data generated or analysed during this study will be included in the subsequent results publication

### IPD sharing plan summary

Published as a supplement to the results publication

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			28/06/2023	No	No